Mantle Cell Lymphoma (MCL) Clinical Trial
Official title:
An Open Label, Single Arm, Multicenter Phase II Study of the Efficacy and Safety of LP-168 Monotherapy for Recurrent or Refractory Mantle Cell Lymphoma
This is an open-label, single arm, multi-center Phase 2 study of oral LP-168 in patients with mantle cell lymphoma who are failed or relapsed after remission or intolerated to Bruton's tyrosine kinase (BTK) inhibitor.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06043011 -
Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms
|
||
| Active, not recruiting |
NCT04477486 -
Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma
|
Phase 2 | |
| Recruiting |
NCT05665530 -
A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib in Participants With R/R Hematologic Malignancies
|
Phase 1 | |
| Terminated |
NCT03571828 -
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma
|
Phase 1 | |
| Terminated |
NCT02914938 -
A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma
|
Phase 1 | |
| Recruiting |
NCT04049513 -
ENABLE (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy)
|
Phase 1 | |
| Recruiting |
NCT03869619 -
REal World Data in LYmphoma and Survival in Adults
|
||
| Active, not recruiting |
NCT04830137 -
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
|
Phase 1 | |
| Recruiting |
NCT03547115 -
A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML
|
Phase 1 | |
| Recruiting |
NCT04186520 -
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT04767308 -
Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies
|
Early Phase 1 | |
| Active, not recruiting |
NCT02213926 -
An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma
|
Phase 2 | |
| Completed |
NCT03877055 -
A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03265158 -
Blood Immunophenotyping in Staging of Indolent B-cell Lymphomas V1.0
|
N/A | |
| Enrolling by invitation |
NCT04488354 -
Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T
|
Phase 1 | |
| Recruiting |
NCT05720052 -
A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT02362035 -
ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05406154 -
Ibrutinib Combined With Bendamustine and Rituximab in Newly Diagnosed Mantle Cell Lymphoma Patients Who Aged > 65 Years
|
||
| Recruiting |
NCT05951959 -
A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma
|
Phase 2 | |
| Active, not recruiting |
NCT02717624 -
A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL
|
Phase 1 |